The immune checkpoints CTLA-4 and PD-L1 in carcinomas of the uterine cervix

43Citations
Citations of this article
33Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Background: Evasion of immune control is a major feature of malignant tumors. This tumor aspect is poorly studied in cervical lesions. Aim of the study: To investigate the expression of PD-L1 and CTLA-4 in lesions of the uterine cervix. Material and methods: Sixty-three cervical lesions from 52 patients were immunohistochemically studied. The 63 lesions included 27 invasive adenocarcinomas, 19 squamous cell carcinomas (SCCs), 7 adenocarcinomas in situ, and 10 high-grade squamous intraepithelial lesions (CIN3). Results: CTLA-4 and PD-L1 tumor cell expression was found in 61.5 % and 26.9 % of the invasive cases, respectively. CTLA-4 tumor cell expression and PD-L1 tumor and immune cell expression were more often found in SCCs than in adenocarcinomas. CTLA-4 tumor cell expression was more often found in advanced FIGO tumors. PD-L1 and CTLA-4 immune cell expression was associated with lymph node metastasis. CTLA-4 expression did not affect survival. The prognosis was worse for PD-L1-expressing tumors. Conclusion: CTLA-4 and PD-L1 are potential therapeutic targets in cervical cancer.

Cite

CITATION STYLE

APA

Karpathiou, G., Chauleur, C., Mobarki, M., & Peoc’h, M. (2020). The immune checkpoints CTLA-4 and PD-L1 in carcinomas of the uterine cervix. Pathology Research and Practice, 216(1). https://doi.org/10.1016/j.prp.2019.152782

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free